AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 368817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30122055 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for class attendance and weight loss
Number of subjects: 1595
Study 30122055 — intervention group
Group type: COMPARATOR
Intervention: Financial incentives for class attendance only
Number of subjects: 1595
Study 28439716 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic drugs
Number of subjects: 111346
Study 28439716 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs
Number of subjects: 111346
Study 25273886 — intervention group
Group type: EXPERIMENTAL
Intervention: None/Trace PVR
Number of subjects: 2434
Study 25273886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild PVR
Number of subjects: 2434
Study 25273886 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/Severe PVR
Number of subjects: 2434
Study 23102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fever control strategy (acetaminophen, physical cooling); acetaminophen dose: 2275 mg
Number of subjects: 200
Study 23102531 — intervention group
Group type: COMPARATOR
Intervention: Permissive fever control strategy; acetaminophen dose: 0 mg
Number of subjects: 200
Study 22132651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined VHA/VHB vaccine (HAB group)
Number of subjects: 596
Study 22132651 — intervention group
Group type: COMPARATOR
Intervention: Concomitant VHA and VHB vaccines (ENG+HAV group)
Number of subjects: 596
Study 22132651 — intervention group
Group type: COMPARATOR
Intervention: Concomitant VHA and VHB vaccines (HBVX+VAQ group)
Number of subjects: 596
Study 19368782 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated subunit influenza vaccine Influvac®
Number of subjects: 6415
Study 16344276 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet about chemotherapy (n = 72)
Number of subjects: 145
Study 16344276 — intervention group
Group type: COMPARATOR
Intervention: No booklet (Control group, n = 73)
Number of subjects: 145
Study 15292765 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 222
Study 15292765 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation
Number of subjects: 222
Study 11533336 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-flow NCPAP
Number of subjects: 24
Study 11533336 — intervention group
Group type: COMPARATOR
Intervention: Constant-flow NCPAP
Number of subjects: 24
Study 9032742 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 437
Study 9032742 — intervention group
Group type: COMPARATOR
Intervention: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg
Number of subjects: 437
Study 9032742 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 437
Study 8060436 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol powder 200 micrograms inhaled every 4 hours (Group I)
Number of subjects: 15
Study 8060436 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol nebulized solution 2.5 mg inhaled every 4 hours (Group II)
Number of subjects: 15
Study 30859944 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (flexible-dose 1-4mg/day)
Number of subjects: 187
Study 28449955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 144
Study 28449955 — intervention group
Group type: COMPARATOR
Intervention: No oral naltrexone (7-day washout period)
Number of subjects: 144
Study 28449955 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal status (not on parole or probation)
Number of subjects: 144
Study 28449955 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent opioid detoxification type (longer-term detoxification program)
Number of subjects: 144
Study 26284539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Number of subjects: 38
Study 26284539 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (no treatment intervention specified)
Number of subjects: 38
Study 26284539 — intervention group
Group type: EXPERIMENTAL
Intervention: IL28B CC genotype
Number of subjects: 38
Study 25098489 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic [Lactobacillus acidophilus NCFM (10(9) CFU) and cellobiose (5 g)]
Number of subjects: 18
Study 25098489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine diluted with normal saline (3 mL of 1% lidocaine + epinephrine in 30 mL of bacteriostatic 0.9% sodium chloride in a 1:10 ratio)
Number of subjects: 31
Study 23134997 — intervention group
Group type: COMPARATOR
Intervention: Buffered lidocaine (5 mL of 8.4% sodium bicarbonate solution and 50 mL of 1% lidocaine + epinephrine in a 1:10 ratio)
Number of subjects: 31
Study 19665403 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus true or non-penetrating acupuncture
Number of subjects: 352
Study 19665403 — intervention group
Group type: COMPARATOR
Intervention: Advice and exercise
Number of subjects: 352
Study 17804079 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 326
Study 17804079 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused therapy
Number of subjects: 326
Study 17804079 — intervention group
Group type: COMPARATOR
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 326
Study 17804079 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies (short-term and long-term)
Number of subjects: 326
Study 15754410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soy milk
Number of subjects: 28
Study 15754410 — intervention group
Group type: COMPARATOR
Intervention: Regular soy milk
Number of subjects: 28
Study 14574055 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-guided treatment
Number of subjects: 69
Study 14574055 — intervention group
Group type: COMPARATOR
Intervention: Clinical score treatment (Control)
Number of subjects: 69
Study 10589358 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX)
Number of subjects: 50
Study 10589358 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 50
Study 8933780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 200 micrograms once daily
Number of subjects: 10
Study 8933780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1805294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day PO)
Number of subjects: 21
Study 1805294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1805294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 21
Study 6425713 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tryptophan (40 mg/kg body weight)
Number of subjects: 11
Study 6425713 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 11
Study 6425713 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tryptophan
Number of subjects: 11
Study 6425713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30652930 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based strength-training program
Number of subjects: 25
Study 30652930 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise program followed by automated telephone calls
Number of subjects: 25
Study 31227374 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty with or without concurrent turbinate surgery
Number of subjects: 203
Study 31227374 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 203
Study 29698106 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of MS-Contin (morphine)
Number of subjects: 21
Study 26593548 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCC
Number of subjects: 45
Study 26593548 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCC+beef
Number of subjects: 45
Study 26593548 — intervention group
Group type: EXPERIMENTAL
Intervention: heme+fish
Number of subjects: 45
Study 26593548 — intervention group
Group type: EXPERIMENTAL
Intervention: heme+chicken
Number of subjects: 45
Study 26593548 — intervention group
Group type: EXPERIMENTAL
Intervention: heme+beef
Number of subjects: 45
Study 26593548 — intervention group
Group type: EXPERIMENTAL
Intervention: casein, collagen, albumin
Number of subjects: 45
Study 26593548 — intervention group
Group type: COMPARATOR
Intervention: heme alone
Number of subjects: 45
Study 25041494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg in 50 ml infusion
Number of subjects: 24
Study 25041494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg in 250 ml infusion
Number of subjects: 24
Study 25041494 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study 25041494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg (50 ml and 250 ml)
Number of subjects: 24
Study 22926600 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 29
Study 22926600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18455908 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (1Hz) with exposure therapy
Number of subjects: 9
Study 18455908 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) with exposure therapy
Number of subjects: 9
Study 17485893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride (15 mg or 30 mg)
Number of subjects: 46
Study 17485893 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (1.25 mg or 2.5 mg)
Number of subjects: 46
Study 15001191 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olmesartan
Number of subjects: 12
Study 15001191 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg olmesartan
Number of subjects: 12
Study 15001191 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg olmesartan
Number of subjects: 12
Study 15001191 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan (all doses)
Number of subjects: 12
Study 15001191 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 11260006 — intervention group
Group type: EXPERIMENTAL
Intervention: F6‐1,25(OH)2D3 (5 microg in 0.1 g of petrolatum)
Number of subjects: 15
Study 11260006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 g of petrolatum)
Number of subjects: 15
Study 11260006 — intervention group
Group type: EXPERIMENTAL
Intervention: F6‐1,25(OH)2D3 (50 microg g‐1 of petrolatum) applied to all lesions
Number of subjects: 15
Study 9732338 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1148
Study 9732338 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1148
Study 7999600 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate solution (1 mg/ml)
Number of subjects: 474
Study 7999600 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol solution (50 micrograms/ml)
Number of subjects: 474
Study 3189725 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer A
Number of subjects: 29
Study 3189725 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer B
Number of subjects: 29
Study 3189725 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer C
Number of subjects: 29
Study 3189725 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen extracts from manufacturer D
Number of subjects: 29
Study 3189725 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST (Pharmacia) and EAST (Kallestad) tests
Number of subjects: 29
Study 3189725 — intervention group
Group type: EXPERIMENTAL
Intervention: Content of major allergens in extracts
Number of subjects: 29
Study 31325822 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent cognitive-behavioral therapy (adapted for lower socioeconomic groups or standard) + 8 weeks of nicotine patches
Number of subjects: 0
Study 31325822 — intervention group
Group type: COMPARATOR
Intervention: Smokers with no history of SUDs
Number of subjects: 0
Study 28086872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 80
Study 28086872 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 80
Study 26111351 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostvac-VF vaccine followed by docetaxel chemotherapy (Arm A, n = 6)
Number of subjects: 10
Study 26111351 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel chemotherapy alone (Arm B, n = 2)
Number of subjects: 10
Study 23424237 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily with bendroflumethiazide 1.25 mg (CB)
Number of subjects: 0
Study 23424237 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg twice daily with placebo (CP)
Number of subjects: 0
Study 21894078 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol mixed with 20 ml of sugar syrup
Number of subjects: 121
Study 21894078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 21894078 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol
Number of subjects: 121
Study 19165648 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 925
Study 19165648 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg twice daily
Number of subjects: 925
Study 17115390 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 per cent glyceryl trinitrate (GTN) ointment
Number of subjects: 82
Study 17115390 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (petroleum jelly)
Number of subjects: 82
Study 15209320 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected Increase
Number of subjects: 40
Study 15209320 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected Similar
Number of subjects: 40
Study 15209320 — intervention group
Group type: COMPARATOR
Intervention: Control Increase
Number of subjects: 40
Study 15209320 — intervention group
Group type: COMPARATOR
Intervention: Control Similar
Number of subjects: 40
Study 11573042 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 179
Study 11573042 — intervention group
Group type: COMPARATOR
Intervention: No drains placed
Number of subjects: 179
Study 9573911 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (1 day per week for 6 weeks)
Number of subjects: 29
Study 8169417 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for 10 days
Number of subjects: 43
Study 8169417 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial treatment alone
Number of subjects: 43
Study 2901037 — intervention group
Group type: EXPERIMENTAL
Intervention: Single perioperative course of adjuvant combination chemotherapy beginning within 36 hours of mastectomy
Number of subjects: 1229
Study 2901037 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of conventionally timed adjuvant chemotherapy starting 25 to 32 days after operation
Number of subjects: 1229
Study 2901037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both the perioperative cycle and the conventionally timed regimen
Number of subjects: 1229
Study 2901037 — intervention group
Group type: COMPARATOR
Intervention: Overall survival differences favored the longer treatments
Number of subjects: 1229
Study 31302092 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked-color imaging (LCI)
Number of subjects: 379
Study 31302092 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-laser imaging (BLI)-bright
Number of subjects: 379
Study 31302092 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 379
Study 30400688 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis (AR) prevalence in children
Number of subjects: 0
Study 30400688 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study 30400688 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of allergic diseases
Number of subjects: 0
Study 30400688 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to smoking or dust environment
Number of subjects: 0
Study 30400688 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to smoking environment during pregnancy
Number of subjects: 0
Study 30400688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet feeding history
Number of subjects: 0
Study 27266848 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Day dorm room isolation intervention
Number of subjects: 590
Study 27266848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no isolation)
Number of subjects: 590
Study 25302462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular low-level laser therapy (LLLT)
Number of subjects: 101
Study 25302462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 23229976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist‐provided telephone MTM consultation
Number of subjects: 120
Study 23229976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 20297611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 50 microg
Number of subjects: 19
Study 20297611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 100 microg
Number of subjects: 19
Study 20297611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 200 microg
Number of subjects: 19
Study 20297611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) (all doses)
Number of subjects: 19
Study 20297611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS)
Number of subjects: 19
Study 17636302 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) of atrial fibrillation
Number of subjects: 221
Study 15864506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anaesthesia controlled by EEG monitoring (Narcotrend or BIS)
Number of subjects: 120
Study 15864506 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil anaesthesia controlled by clinical parameters
Number of subjects: 120
Study 15864506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI concentrations adjusted according to clinical parameters or EEG target values
Number of subjects: 120
Study 12412840 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes (3.95% THC)
Number of subjects: 0
Study 12412840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg)
Number of subjects: 0
Study 12412840 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study 10222703 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 0
Study 10222703 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 7503401 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms b.i.d.
Number of subjects: 304
Study 7503401 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms q.i.d.
Number of subjects: 304
Study 7503401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 2129379 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA)
Number of subjects: 0
Study 2129379 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 0
Study 6987024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg daily
Number of subjects: 13
Study 6987024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31923242 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of oral Mg++ citrate (n = 66)
Number of subjects: 132
Study 31923242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 132
Study 31923242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mg++ and placebo)
Number of subjects: 132
Study 31598912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB)
Number of subjects: 740
Study 31598912 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 740
Study 28409402 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus tamsulosin for 24 weeks
Number of subjects: 90
Study 28409402 — intervention group
Group type: COMPARATOR
Intervention: ADT for 24 weeks
Number of subjects: 90
Study 26371261 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAMOND care after implementation (DCA)
Number of subjects: 1578
Study 26371261 — intervention group
Group type: COMPARATOR
Intervention: Usual care before implementation (UCB)
Number of subjects: 1578
Study 26371261 — intervention group
Group type: COMPARATOR
Intervention: Usual care after implementation (UCA)
Number of subjects: 1578
Study 26371261 — intervention group
Group type: COMPARATOR
Intervention: Usual care in comparison clinics (UC)
Number of subjects: 1578
Study 25281169 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site satisfaction survey
Number of subjects: 457
Study 25281169 — intervention group
Group type: COMPARATOR
Intervention: Mail-out satisfaction survey
Number of subjects: 457
Study 22659994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 16 mg galantamine plus 20 mg memantine
Number of subjects: 232
Study 22659994 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg galantamine alone
Number of subjects: 232
Study 22659994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 22659994 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 232
Study 22659994 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (as part of the combination regimen or as mono treatment)
Number of subjects: 232
Study 22659994 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of amnestic MCI with presumed AD etiology
Number of subjects: 232
Study 22659994 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of amnestic MCI presumably due to other etiologies
Number of subjects: 232
Study 20817382 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual motivational interviewing (MI) sessions
Number of subjects: 382